drugset / Trial / NCT04236011
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
Phase 0
Unknown
15 enrolled
Shanghai Changzheng Hospital
Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, multi-center prospective study to determine the safety and efficacy of GC012F CAR-T cells in patients diagnosed with BCMA+ refractory/relapsed multiple myeloma (r/r MM).
Timeline
- Start
- 2020-01-16
- Primary completion
- 2022-07-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | GC012F | Cell therapy | 500000 cells/kg | Intravenous |